ArticleDrug design, development and therapy2026
Remimazolam and Postoperative Delirium in Patients with Hyperlipidemia: A Retrospective Cohort Study with Target Trial Emulation Analysis.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of Remimazolam on Postoperative Delirium in Elderly Surgical Patients: A Critical Review of Pharmacological Mechanisms and Clinical Evidence.Drug design, development and therapy · 2026Review
- Effect of remazolam combined with hydromorphone postoperative analgesia on cognitive function in elderly patients undergoing hip replacement.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hyperlipidemia increases postoperative delirium (POD) risk via neuroinflammation; however, effective pharmacological interventions to mitigate POD in this population remain limited. Remimazolam has been reported to reduce perioperative stress and modulate neuroinflammatory responses. We investigated the effect of remimazolam on POD incidence in surgical patients with hyperlipidemia. Patients and Methods: In this retrospective cohort study, we enrolled 1123 patients with hyperlipidemia who underwent surgery under general anesthesia with or without remimazolam at a single institution. The primary outcome measure was POD incidence within 3 days postoperatively. To assess the impact of remimazolam on POD, a target trial emulation framework was applied to enhance control of confounders and strengthen causal inference. We additionally investigated the dose-response relationship between remimazolam exposure and POD. Results: POD incidence in the remimazolam group was 13.8%, which was 7.2% lower than that in the non-remimazolam group (P<0.01). Additionally, delirium severity (median score: 9 vs 10, P<0.01) and cognitive impairment incidence at 6 months postoperatively (4.4% vs 8.3%, P<0.05) were lower in the remimazolam group. The target trial emulation further confirmed the protective effects of remimazolam on POD (adjusted risk difference [aRD]: -5.3%, P=0.016), delirium severity (aRD: -2.238, P<0.001), and cognitive dysfunction incidence at 6 months postoperatively (aRD: -3.97%, P=0.019). Dose-response analysis showed a significant reduction in POD incidence when the total remimazolam dose was ≥10.29 mg or the maintenance rate was ≥0.51 mg kg Conclusion: Remimazolam significantly reduced POD incidence and severity in patients with hyperlipidemia and improved cognitive function at 6 months postoperatively. However, prospective studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.